Welcome and Introduction
Therapeutic Development Beyond Anti–PD-1/PD-L1 in Urothelial Carcinoma
Therapeutic Strategies for Metastatic Urothelial Carcinoma Previously Treated With Chemotherapy and/or Checkpoint Inhibitors
Ongoing Research and New Horizons for Urothelial Carcinoma Treatment
Audience Question and Answer Session
Petros Grivas, MD, PhD
Clinical Director, Genitourinary Cancers Program
Division of Medical Oncology
Department of Medicine
University of Washington
Seattle Cancer Care Alliance
Cora Sternberg, MD
Professor of Medicine
Department of Hematology/Oncology
Weill Cornell Medicine
New York, New York
The goal of this activity is to improve the knowledge, confidence, competence, and performance of learners to integrate new agents and recent findings into the treatment of patients with urothelial carcinoma.
This program is intended for physicians and other healthcare providers who care for patients with urothelial carcinoma.
Upon completion of this activity, participants should be able to:
- Plan therapy for patients with urothelial carcinoma and disease progression during or following platinum-containing chemotherapy and/or immune checkpoint inhibitor therapy
- Describe the unique mechanisms of action of novel targeted therapies for the treatment of advanced urothelial carcinoma
- Identify patients, through predictive biomarkers, most likely to respond to personalized targeted therapies
- Discuss ongoing clinical trials investigating targeted systemic therapies in the treatment advanced urothelial carcinoma
Joint Accreditation Statement
In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Physician Continuing Medical Education
CCO designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
American Board of Internal Medicine Maintenance of Certification
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
American Board of Pathology Continuing Certification
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 Lifelong Learning points in the American Board of Pathology’s Maintenance of Certification (MOC) Program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit learner completion information to ACCME for the purpose of granting ABPath Continuing Certification (formerly Maintenance of Certification or MOC) credit.
Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.